 Corey Hayes
Concepts (183)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 28 | 2024 | 575 | 5.380 |
Why?
| | Opioid-Related Disorders | 14 | 2024 | 393 | 4.670 |
Why?
| | Chronic Pain | 12 | 2024 | 182 | 4.150 |
Why?
| | Buprenorphine | 5 | 2024 | 145 | 3.120 |
Why?
| | Drug Overdose | 8 | 2024 | 159 | 2.970 |
Why?
| | Opiate Substitution Treatment | 5 | 2024 | 99 | 2.890 |
Why?
| | Alcoholism | 4 | 2022 | 235 | 2.440 |
Why?
| | Telemedicine | 12 | 2025 | 469 | 2.430 |
Why?
| | Veterans | 7 | 2024 | 574 | 1.910 |
Why?
| | Aftercare | 2 | 2023 | 72 | 1.600 |
Why?
| | Patient Discharge | 3 | 2024 | 321 | 1.580 |
Why?
| | Medicare | 3 | 2023 | 247 | 1.550 |
Why?
| | Quality of Life | 6 | 2023 | 851 | 1.530 |
Why?
| | United States | 25 | 2025 | 4955 | 1.430 |
Why?
| | Pain | 4 | 2022 | 387 | 1.320 |
Why?
| | Narcotic Antagonists | 3 | 2024 | 136 | 1.240 |
Why?
| | Substance-Related Disorders | 4 | 2025 | 611 | 1.140 |
Why?
| | Retrospective Studies | 19 | 2025 | 6263 | 1.130 |
Why?
| | Humans | 55 | 2025 | 50503 | 1.030 |
Why?
| | Delivery of Health Care | 4 | 2024 | 303 | 1.030 |
Why?
| | Patient Acceptance of Health Care | 4 | 2023 | 342 | 0.920 |
Why?
| | Adult | 24 | 2025 | 13577 | 0.910 |
Why?
| | Naltrexone | 1 | 2024 | 59 | 0.910 |
Why?
| | Methadone | 1 | 2024 | 183 | 0.850 |
Why?
| | Social Media | 2 | 2023 | 99 | 0.850 |
Why?
| | Fee-for-Service Plans | 1 | 2023 | 18 | 0.840 |
Why?
| | Middle Aged | 21 | 2025 | 12611 | 0.810 |
Why?
| | Male | 27 | 2025 | 25907 | 0.770 |
Why?
| | Internet | 1 | 2024 | 259 | 0.760 |
Why?
| | Female | 29 | 2025 | 27081 | 0.760 |
Why?
| | Aged | 16 | 2024 | 9741 | 0.750 |
Why?
| | United States Department of Veterans Affairs | 5 | 2025 | 291 | 0.720 |
Why?
| | Financing, Personal | 2 | 2024 | 17 | 0.650 |
Why?
| | Hospitalization | 1 | 2023 | 675 | 0.640 |
Why?
| | Arkansas | 9 | 2024 | 1985 | 0.620 |
Why?
| | Tramadol | 3 | 2024 | 30 | 0.610 |
Why?
| | Hypertension | 1 | 2023 | 544 | 0.610 |
Why?
| | Back Pain | 1 | 2018 | 38 | 0.600 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 1610 | 0.590 |
Why?
| | Osteoarthritis | 1 | 2018 | 61 | 0.580 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 484 | 0.540 |
Why?
| | Hyperalgesia | 1 | 2017 | 55 | 0.540 |
Why?
| | Young Adult | 9 | 2024 | 4102 | 0.520 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2015 | 7 | 0.500 |
Why?
| | Dextropropoxyphene | 1 | 2015 | 6 | 0.500 |
Why?
| | Hospitals, Rural | 2 | 2025 | 21 | 0.480 |
Why?
| | Urban Health Services | 1 | 2014 | 21 | 0.470 |
Why?
| | Hospitals, Urban | 2 | 2025 | 26 | 0.450 |
Why?
| | Medicare Part D | 1 | 2013 | 3 | 0.430 |
Why?
| | Health Services Accessibility | 4 | 2023 | 424 | 0.420 |
Why?
| | Rural Health Services | 1 | 2014 | 169 | 0.400 |
Why?
| | Choice Behavior | 1 | 2013 | 83 | 0.390 |
Why?
| | Cohort Studies | 3 | 2024 | 1452 | 0.390 |
Why?
| | Mental Health Services | 1 | 2014 | 202 | 0.390 |
Why?
| | Adolescent | 7 | 2024 | 6443 | 0.370 |
Why?
| | Methamphetamine | 2 | 2024 | 194 | 0.370 |
Why?
| | Students, Pharmacy | 1 | 2013 | 124 | 0.370 |
Why?
| | Pandemics | 6 | 2024 | 563 | 0.340 |
Why?
| | Depression | 1 | 2014 | 582 | 0.330 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2014 | 383 | 0.330 |
Why?
| | Pain Measurement | 2 | 2021 | 270 | 0.310 |
Why?
| | Propensity Score | 2 | 2018 | 136 | 0.280 |
Why?
| | Aged, 80 and over | 3 | 2023 | 3226 | 0.280 |
Why?
| | Drug Prescriptions | 2 | 2019 | 97 | 0.280 |
Why?
| | Databases, Factual | 2 | 2022 | 673 | 0.260 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 591 | 0.260 |
Why?
| | Models, Educational | 1 | 2025 | 32 | 0.240 |
Why?
| | Education, Medical, Continuing | 1 | 2025 | 71 | 0.230 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 56 | 0.230 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 87 | 0.230 |
Why?
| | Outpatients | 1 | 2025 | 117 | 0.230 |
Why?
| | Rural Population | 3 | 2023 | 554 | 0.220 |
Why?
| | Amphetamine-Related Disorders | 1 | 2024 | 93 | 0.210 |
Why?
| | Mortality | 1 | 2023 | 96 | 0.210 |
Why?
| | Hospitals, Private | 1 | 2022 | 2 | 0.210 |
Why?
| | Quality Improvement | 1 | 2025 | 209 | 0.210 |
Why?
| | Prevalence | 3 | 2025 | 971 | 0.200 |
Why?
| | Spinal Cord Injuries | 1 | 2023 | 53 | 0.200 |
Why?
| | Prospective Studies | 2 | 2022 | 2378 | 0.200 |
Why?
| | Central Nervous System Stimulants | 1 | 2024 | 209 | 0.190 |
Why?
| | Accidents | 1 | 2021 | 20 | 0.190 |
Why?
| | Neuralgia | 1 | 2023 | 66 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 118 | 0.190 |
Why?
| | Follow-Up Studies | 3 | 2024 | 2242 | 0.190 |
Why?
| | Naloxone | 1 | 2020 | 81 | 0.160 |
Why?
| | Program Evaluation | 1 | 2021 | 349 | 0.160 |
Why?
| | Hydrocodone | 3 | 2024 | 20 | 0.160 |
Why?
| | Oxycodone | 3 | 2024 | 27 | 0.160 |
Why?
| | Health Status | 2 | 2018 | 299 | 0.160 |
Why?
| | Prescription Drug Misuse | 1 | 2019 | 34 | 0.160 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 266 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2019 | 18 | 0.160 |
Why?
| | Depressive Disorder, Major | 1 | 2020 | 151 | 0.150 |
Why?
| | Longitudinal Studies | 2 | 2018 | 735 | 0.150 |
Why?
| | Odds Ratio | 1 | 2020 | 551 | 0.150 |
Why?
| | Health Status Indicators | 1 | 2017 | 82 | 0.140 |
Why?
| | Pyridones | 1 | 2016 | 34 | 0.130 |
Why?
| | Physicians | 1 | 2019 | 232 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 253 | 0.120 |
Why?
| | Warfarin | 1 | 2016 | 83 | 0.120 |
Why?
| | Pyrazoles | 1 | 2016 | 111 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2016 | 164 | 0.120 |
Why?
| | Veterans Health | 1 | 2014 | 62 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 279 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 573 | 0.110 |
Why?
| | Atrial Fibrillation | 1 | 2016 | 188 | 0.110 |
Why?
| | Anticoagulants | 1 | 2016 | 256 | 0.110 |
Why?
| | Cost Savings | 1 | 2013 | 57 | 0.100 |
Why?
| | Risk | 3 | 2020 | 324 | 0.100 |
Why?
| | Logistic Models | 1 | 2015 | 900 | 0.100 |
Why?
| | Acetaminophen | 1 | 2015 | 276 | 0.100 |
Why?
| | Data Collection | 1 | 2013 | 280 | 0.100 |
Why?
| | Chromans | 1 | 2011 | 35 | 0.090 |
Why?
| | Kidney Tubules, Proximal | 1 | 2011 | 62 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2013 | 278 | 0.090 |
Why?
| | Vitamin E | 1 | 2011 | 78 | 0.090 |
Why?
| | Cell Death | 1 | 2011 | 175 | 0.090 |
Why?
| | Stroke | 1 | 2016 | 495 | 0.090 |
Why?
| | Mitochondria | 1 | 2011 | 399 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 2 | 2020 | 63 | 0.070 |
Why?
| | Neoplasms | 1 | 2018 | 1251 | 0.070 |
Why?
| | Risk Factors | 3 | 2022 | 3724 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2011 | 772 | 0.070 |
Why?
| | Psychometrics | 2 | 2018 | 232 | 0.070 |
Why?
| | Mental Health | 2 | 2018 | 228 | 0.060 |
Why?
| | Medically Underserved Area | 1 | 2025 | 47 | 0.060 |
Why?
| | Animals | 2 | 2017 | 13124 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2018 | 1197 | 0.060 |
Why?
| | Patient Admission | 1 | 2024 | 76 | 0.060 |
Why?
| | Prescriptions | 1 | 2023 | 10 | 0.060 |
Why?
| | Focus Groups | 1 | 2025 | 194 | 0.060 |
Why?
| | Insurance Coverage | 1 | 2024 | 110 | 0.050 |
Why?
| | Controlled Substances | 1 | 2022 | 6 | 0.050 |
Why?
| | Capsaicin | 1 | 2023 | 16 | 0.050 |
Why?
| | Spatial Analysis | 1 | 2022 | 19 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2023 | 114 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2025 | 220 | 0.050 |
Why?
| | Public Health | 1 | 2025 | 199 | 0.050 |
Why?
| | Qualitative Research | 1 | 2025 | 349 | 0.050 |
Why?
| | Social Class | 1 | 2022 | 94 | 0.050 |
Why?
| | Health Surveys | 1 | 2022 | 239 | 0.050 |
Why?
| | Caregivers | 1 | 2023 | 217 | 0.040 |
Why?
| | Administration, Intranasal | 1 | 2020 | 30 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 30 | 0.040 |
Why?
| | Drug Costs | 1 | 2020 | 38 | 0.040 |
Why?
| | Travel | 1 | 2019 | 36 | 0.040 |
Why?
| | Risk-Taking | 1 | 2019 | 107 | 0.040 |
Why?
| | Community Pharmacy Services | 1 | 2020 | 66 | 0.040 |
Why?
| | Smoking | 1 | 2022 | 507 | 0.040 |
Why?
| | Urban Population | 1 | 2019 | 151 | 0.040 |
Why?
| | Acute Pain | 1 | 2017 | 11 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 206 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 415 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 53 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 583 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 2452 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 623 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 170 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 128 | 0.030 |
Why?
| | Pyridines | 1 | 2016 | 131 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 434 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 930 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 468 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2016 | 978 | 0.030 |
Why?
| | tert-Butylhydroperoxide | 1 | 2011 | 5 | 0.020 |
Why?
| | Oligomycins | 1 | 2011 | 7 | 0.020 |
Why?
| | Proton-Translocating ATPases | 1 | 2011 | 9 | 0.020 |
Why?
| | alpha-Tocopherol | 1 | 2011 | 9 | 0.020 |
Why?
| | Reactive Nitrogen Species | 1 | 2011 | 23 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2011 | 36 | 0.020 |
Why?
| | Cell Respiration | 1 | 2011 | 41 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2011 | 60 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2011 | 41 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 372 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2011 | 190 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 2935 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2011 | 232 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 207 | 0.020 |
Why?
| | Cell Survival | 1 | 2011 | 589 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 409 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2011 | 1571 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 5283 | 0.020 |
Why?
| | Apoptosis | 1 | 2011 | 1097 | 0.020 |
Why?
|
|
Hayes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|